Stockscreener 앱 받기
0.00
100.00%
-0.36
Avenue Therapeutics Inc 주식(ATXI)의 최신 뉴스
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - The National Law Review
Postoperative Pain Management Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - Business Upturn
Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
State Street (NYSE: STT) discloses 5.5% beneficial stake in Lexeo Therapeutics (LXEO) - Stock Titan
Aprea Therapeutics, Inc. (APRE) stock price, news, quote and history - Yahoo Finance Singapore
State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene - Stock Titan
Price to earnings forward of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Aldeyra Therapeutics (NASDAQ: ALDX) leases new Concord headquarters space - Stock Titan
Change Agents Corporation (CHGA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Avenue Therapeutics, Inc. Revenue Breakdown – OTC:ATXI - TradingView
Frontier tech research, news & data - MLQ.ai
Circio, Avenue Biosciences Partner on Gene Therapy Protein Expression - Contract Pharma
Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing - Stock Titan
Turn Therapeutics Inc.Common Stock (TTRX) Stock Price, News, Quote & History - FinancialContent
TG Therapeutics Initiates Phase 2 Trial of BRIUMVI in Treatment-Resistant Schizophrenia - Quiver Quantitative
Enterprise value to EBITDA forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to sales forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to book forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to sales forward of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Enterprise value to EBIT forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to earnings forward of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Avenue Therapeutics, Inc. Actuals & Estimates (OTC:ATXI) - TradingView
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Business Wire
Avenue Therapeutics (ATXI) Q1 2026 earnings summary - Quartr
Avenue Therapeutics (ATXI) Q3 2024 earnings summary - Quartr
Avenue Therapeutics (ATXI) AGM 2024 Summary - Quartr
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering - Business Wire
Definium Therapeutics, Inc. Announces Proposed Public Offering - BioSpace
Fortress Biotech StockSaturday deep dive on the business model - AD HOC NEWS
Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - StreetInsider
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - StreetInsider
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - TradingView
Summit Therapeutics Announces Proposed Public Offering of Common Stock - FinancialContent
Tango Therapeutics Announces Proposed $500 Million Public Offering - The Manila Times
Neuro stocks outpace broader markets as psychedelics, Axsome shine - BioWorld News
Chiesi (KALV) offers $27.00/share; HSR, German and Italian clearances noted - Stock Titan
Relay Therapeutics Announces Proposed Public Offering of Common Stock - Investing News Network
Madison Avenue entities (INDV) disclose 4.32M-share, ~3.5% stake - Stock Titan
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Click Therapeutics Positions Over-the-Counter Digital Therapeutics as New Growth Avenue - TipRanks
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
MSN Money - MSN
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
AVENUE THERAPEUTICS, INC. 1Q 2026: Net loss $0.7M, Revenue $0— 10-Q Summary - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Avenue Therapeutics (OTC: ATXI) cuts Q1 loss but warns on going concern - Stock Titan
Avenue Therapeutics | 10-Q: Quarterly report - Moomoo
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering - BioSpace
Board elections and auditor vote at MiNK Therapeutics (NASDAQ: INKT) - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Executive pay and audits headline Monte Rosa (NASDAQ: GLUE) 2026 proxy - Stock Titan
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering - The Manila Times
Akebia (NASDAQ: AKBA) plans major increase in authorized common shares - Stock Titan
Abeona Therapeutics (NASDAQ: ABEO) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Intellia Therapeutics
Form S-1/A Hemab Therapeutics Holdi - StreetInsider
Spero Therapeutics (NASDAQ: SPRO) 2026 proxy adds stock increase and new incentive plan - Stock Titan
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Waltham-based Kailera Therapeutics raises $625 million in IPO - Waltham Times
3.42%
0.62%
자본화:
|
볼륨(24시간):